TrialIntensive care medicine2021

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.

Pierre-François Laterre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.